<SEC-DOCUMENT>0001213900-15-005229.txt : 20150716
<SEC-HEADER>0001213900-15-005229.hdr.sgml : 20150716
<ACCEPTANCE-DATETIME>20150716090131
ACCESSION NUMBER:		0001213900-15-005229
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20150714
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150716
DATE AS OF CHANGE:		20150716

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RELMADA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001553643
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				455401931
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55347
		FILM NUMBER:		15990611

	BUSINESS ADDRESS:	
		STREET 1:		546 FIFTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-702-7163

	MAIL ADDRESS:	
		STREET 1:		546 FIFTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CAMP NINE, INC.
		DATE OF NAME CHANGE:	20120706
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k071415_relmadatherap.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington,
D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
July 14, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>RELMADA
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; border-bottom: Black 1.5pt solid"><B>Nevada</B></TD>
    <TD STYLE="width: 2%; padding: 0pt 0pt 1.5pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; border-bottom: Black 1.5pt solid"><B>333-184881</B></TD>
    <TD STYLE="width: 2%; padding: 0pt 0pt 1.5pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt; border-bottom: Black 1.5pt solid"><B>45-5401931</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0pt; text-indent: 0pt"><P STYLE="margin-top: 0; margin-bottom: 0">(State or other jurisdiction</P>
                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">of incorporation)</P></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0pt; text-indent: 0pt">(Commission File Number)</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0pt; text-indent: 0pt"><P STYLE="margin-top: 0; margin-bottom: 0">(IRS Employer</P>
                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><B>757 Third Avenue, Suite 2018</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><B>New York, NY</B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding: 0pt 0pt 1.5pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; text-indent: 0pt"><B>10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0pt; text-indent: 0pt">(Address of principal executive offices)</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0pt; text-indent: 0pt">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code<B> (212) 376-5742</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B>546 5<SUP>th</SUP> Avenue, 14<SUP>th</SUP> Floor, New York, NY 10036</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">(Former name or former address, if changed since last report)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center; padding: 0pt; text-indent: 0pt">&#9744;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center; padding: 0pt; text-indent: 0pt">&#9744;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center; padding: 0pt; text-indent: 0pt">&#9744;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center; padding: 0pt; text-indent: 0pt">&#9744;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><B>Item 5.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements
of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>Board of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 14, 2015, Relmada Therapeutics,
Inc.&rsquo;s (the &ldquo;Company&rdquo;) board of directors appointed Charles J. Casamento as a director of the Company. Mr. Casamento
will chair the Company&rsquo;s newly formed Audit Committee. On July 14, 2015, the board also appointed Sandesh Seth as Chairman
of the Board. Mr. Seth has been a director of the Company since October 2012 and Lead Director since January 2014.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 14, 2015, the Company&rsquo;s
board of directors also formed an Audit Committee and Compensation Committee. Actions taken by these committees are reported to
the full board. The membership of these committees is set forth below.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif"><B>Audit Committee</B></FONT></TD>
    <TD STYLE="width: 2%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 47%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif"><B>Compensation&nbsp;Committee</B></FONT></TD>
    <TD STYLE="width: 2%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Charles J. Casamento*</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Shreeram Agharkar*</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Shreeram Agharkar</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Nabil Yazgi</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Nabil Yazgi</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Sandesh Seth (advisor)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>* </B>Indicates committee chair</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A brief description of the background and business experience
of Mr. Casamento is as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><B>Charles J. Casamento</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">Since
2007 Mr. Casamento  has been Executive Director and Principal of The Sage Group, a health care advisory group specializing
in business development strategies and transactions. Prior to The Sage Group he was President and CEO of Osteologix from
October 2004 until April, 2007. Originally a private VC funded company in Copenhagen, Denmark which had discovered a new drug
for the treatment of Osteoporosis, Mr. Casamento commenced operations and initiated clinical trials in the US, completed a
financing with Rodman &amp; Renshaw and Roth Capital Partners and took the company public through a merger with a public
shell company. The product was eventually acquired by Servier a major French pharmaceutical company. Osteologix was Mr.
Casamento's fifth start up company, all of which were successfully taken public, during his tenure, either through IPOs or
through reverse mergers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">He was
Senior Vice President &amp; General Manager for Pharmaceuticals and Biochemicals at Genzyme. He joined Genzyme in 1985 while it
was an early stage venture backed company and was there during the time Genzyme was taken public. In 2011 Genzyme was acquired
by Sanofi for an estimated $20 Billion. In 1989 he co-founded and later took public, Interneuron Pharmaceuticals (Indevus) which
eventually reached a $1.6 billion market valuation after a weight loss product that was developed during his tenure was approved
by FDA. Indevus was acquired in 2009 by Endo for nearly $1 Billion. In 1993 Mr. Casamento joined RiboGene as Chairman, President
and CEO. He took the Company public and completed several major corporate collaborations and R&amp;D collaboration agreements as
well as a merger with a public corporation in 1998 to form Questcor Pharmaceuticals, where he was Chairman, CEO and President until
August, 2004. He acquired Acthar, a product for West Syndrome and MS, for a $100,000 cash payment plus a 1% royalty. Questcor was
acquired by Mallinckrodt in 2014 at a valuation of $6 Billion and Acthar has revenue at a run rate of $1 Billion for 2014. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">Prior
to joining Genzyme in 1985 Mr. Casamento has held a number of marketing, sales, finance and business development positions with
Novartis, Hoffmann-LaRoche, Johnson &amp; Johnson and American Hospital Supply Corporation where he was Vice President of Business
Development and Strategic Planning for the Critical Care Division from January, 1983 until May, 1985. During his career he has
completed well over 100 major business development/M&amp;A deals which had the effect of enhancing and expediting the growth and
development of his businesses. He took four biotechnology companies public and secured pubic and VC financing for five biotechnology
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">He is
a Director and Board member at KineMed and International Stem Cell Corporation. During his career he has served on the boards of
nine public companies. Mr. Casamento also served as Chairman of the Audit Committee of Astex Pharmaceuticals and is a SOX defined
financial expert. He is a member of the Fordham University Science Council and has been a guest lecturer at Fordham University.
He was previously Vice Chairman of the Catholic Medical Mission Board, a large not for profit organization providing health care
services to third world countries. A graduate of Fordham University in New York City and Iona College in New Rochelle, New York.
Mr. Casamento has a degree in Pharmacy and an MBA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><B>Term of Office</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Mr. Casamento shall remain as a director of
the Company until his successor, if any, is elected or qualified. Mr. Casamento&rsquo;s continuation as a director of the Company
shall be subject to ratification and approval of the shareholders entitled to vote in the 2015 annual meeting of shareholders of
the Company. Mr. Casamento shall be classified as a Class II director and again be up for election at the 2016 annual shareholders
meeting, with a three year term thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">There are no family relationships between our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Transactions with Related Persons</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company does not have any related party transactions
with Mr. Casamento.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Agreements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 14, 2015, Mr. Casamento and
the Company entered into a director agreement (the &ldquo;Agreement&rdquo;). Pursuant to the Agreement, Mr. Casamento will be entitled
to a compensation of $30,000 per year, payable in quarterly installments. for his services as a director of the Company. Mr. Casamento
was also granted 128,825 options (the &ldquo;Options&rdquo;) to purchase shares of the Company&rsquo;s common stock. The Options
shall have a term of 10 years and the exercise price of the Options shall be equal to the share price of the common stock on his
start date as a director, July 14, 2015. The Options shall vest as follows: twenty-five percent (25%) shall vest on the first anniversary
of the grant date and the remaining seventy-five percent (75%) shall thereafter vest in equal quarterly increments of 6.25% of
the initial option grant over the following three year period.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Casamento also entered into an Indemnity
Agreement (the &ldquo;Indemnity Agreement&rdquo;) with the Company, whereby the Company agreed to indemnify Mr. Casamento in certain
situations in connection with his role as a director for the Company.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing summaries do not purport
to be complete and are qualified in their entirety by reference to the Agreement and the Indemnity Agreement which is filed as
Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Events.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issued a press release announcing
the appointment of Mr. Casamento to the Company&rsquo;s Board, a copy of which is filed as Exhibit 99.1 to this report.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Exhibits.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 5%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit No.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 94%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; 10.1</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director Agreement, dated July 14, 2015, by and between Charles J. Casamento and Relmada Therapeutics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director Indemnity Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;99.1</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release, dated July 15, 2015</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">Dated: &nbsp;July 16, 2015</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-indent: 0pt"><B>RELMADA THERAPEUTICS, INC.</B></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; width: 60%; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 36%; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt; text-indent: 0pt">By:</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">/s/ Sergio Traversa</TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">Name:&nbsp;Sergio Traversa</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt">Title:&nbsp;&nbsp;Chief Executive Officer</P></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">4</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0pt; padding: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f8k071415ex10i_relmadatherap.htm
<DESCRIPTION>DIRECTOR AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RELMADA
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">757
Third Avenue, Suite 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">New
York, NY 10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; padding: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 14, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles
J. Casamento</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">P.O.
Box 949</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kenwood,
CA 95452</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dear
Mr. Casamento:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
behalf of Relmada Therapeutics, Inc. (the &ldquo;Company&rdquo;), I would like to welcome you to our team. I would also like to
take this time to confirm our discussions with regard to your position on our Board of Directors starting July 14, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                                                                                                                                                                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0">&nbsp;</TD><TD STYLE="padding: 0">Salary:</TD><TD STYLE="text-align: justify; padding: 0">$30,000
per year, payable in four equal quarterly installments.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0">&nbsp;</TD><TD STYLE="padding: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 72pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Options:</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">128,825
                                         options to purchase shares of the Company&rsquo;s common share $0.001 par value (the
                                         &ldquo;Shares&rdquo;), representing 0.15% of the fully diluted common shares of the Company
                                         as of the Effective Date. The Options shall have a term of 10 years and the exercise
                                         price of the Options shall be equal to the share price of the common stock on your start
                                         date, July 14, 2015. The Options shall vest as follows: twenty-five percent (25%) shall
                                         vest on the first anniversary of the Effective Date (the Grant Date) and the remaining
                                         seventy-five percent (75%) shall thereafter vest in equal quarterly increments of 6.25%
                                         of the initial option Grant over the following three year period. For the avoidance of
                                         doubt, the final installment of Options shall vest on July 14, 2019.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: -72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 72pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Term:</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You
                                         shall remain as a director of the Company from the Effective Date until your successor,
                                         if any, is elected or qualified (the &ldquo;Termination Date&rdquo;). Otherwise, your
                                         continuation as a director of the Company shall be subject to ratification and approval
                                         of the majority shareholders entitled to vote in the 2015 annual meeting of shareholders
                                         of the Company pursuant to the Company&rsquo;s Bylaws and Articles of Incorporation,
                                         as amended. You shall be classified as a Class II director and again be up for election
                                         at the 2016 annual shareholders meeting, with a three year term thereafter. If your position
                                         is terminated prior to the Termination Date, you shall only be entitled to the Salary
                                         payable and the Options that have vested as of such date. You shall also on the date
                                         hereof sign an Indemnification Agreement with the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-align: justify; text-indent: -72pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
light of receiving the Shares, you hereby represent and warrant that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">you
                                         (i) have adequate means of providing for your current needs and possible personal contingencies,
                                         (ii) have no need for liquidity in this investment, (iii) are able to bear the substantial
                                         economic risks of an investment in the Shares for an indefinite period, (iv) at the present
                                         time, can afford a complete loss of such investment, and (v) are an &ldquo;accredited
                                         investor&rdquo; as defined in the Securities Act of 1933, as amended;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">you
                                         do not have a preexisting personal or business relationship with the Company or any of
                                         its directors or executive officers, or by reason of any business or financial experience
                                         or the business or financial experience of any professional advisors who are unaffiliated
                                         with and who are compensated by the Company or any affiliate or selling agent of the
                                         Company, directly or indirectly, could be reasonably assumed to have the capacity to
                                         protect your interests in connection with the investment of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">you
                                         are aware that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 108pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">i.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Shares are not transferable under this Letter Agreement and applicable securities laws;
                                         and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 108pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ii.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Articles of Incorporation and Bylaws of the Company contain provisions that limit or
                                         eliminate the personal liability of the officers, directors and agents of the Company
                                         and indemnify such parties for certain damages relating to the Company, including damages
                                         in connection with the Shares and Options and the good-faith management and operation
                                         of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 144pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">you
                                         acknowledge that the Shares are not currently registered under any registration statement
                                         with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">e.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">you
                                         have not been furnished any offering literature and has not been otherwise solicited
                                         by the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">f.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         Company and its officers, directors and agents have answered all inquiries that you have
                                         made of them concerning the Company or any other matters relating to the formation, operation
                                         and proposed operation of the company and the offering and sale of the Shares;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">g.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">all
                                         information that you have provided to the Company concerning yourself, your financial
                                         position and your knowledge of financial and business matters, including all information
                                         contained herein, is correct and complete as of the date set forth at the end hereof
                                         and may be relied upon, and if there should be any material adverse change in such information
                                         prior to this subscription being accepted, you will immediately provide the Company with
                                         such information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt; padding: 0"></TD><TD STYLE="width: 36pt; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">h.</FONT></TD><TD STYLE="text-align: justify; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">in
                                         rendering the services hereunder and in connection with the Shares, you agree to comply
                                         with the applicable federal and state securities laws, the rules and regulations thereunder,
                                         the rules and regulations of any exchange or quotation service on which the Company&rsquo;s
                                         securities are listed and the rules and regulations of the National Association of Securities
                                         Dealers, Inc.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
behalf of the Company&rsquo;s Board, I would like to thank you for your time and we look forward to working with you closely to
make the Company a success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yours
truly,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding: 0; font-size: 10pt; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Sandesh Seth</FONT></TD>
    <TD STYLE="width: 60%; padding: 0; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandesh
Seth</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lead
Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accepted
as of the date</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">first
above written (the &ldquo;Effective Date&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding: 0; font-size: 10pt; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Charles J. Casamento</FONT></TD>
    <TD STYLE="width: 60%; padding: 0; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles
J. Casamento</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>f8k071415ex10ii_relmadather.htm
<DESCRIPTION>DIRECTOR INDEMNITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 11pt/12.1pt Times New Roman, Times, Serif; margin: 13.55pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/12.1pt Times New Roman, Times, Serif; margin: 13.55pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.3pt">INDEMNIFICATION
AGREEMENT</FONT></P>

<P STYLE="font: 11pt/12.25pt Times New Roman, Times, Serif; margin: 13.65pt 0 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.4pt">THIS
INDEMNIFICATION AGREEMENT (this &ldquo;Agreement&rdquo;) is made and entered into this 14th day of July</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">,
20</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.4pt">15</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">,
by and between Relmada Therapeutics, Inc., a Nevada corporation (the &ldquo;<I>Corporation</I>&rdquo;), and </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.4pt">Charles
J. Casamento</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt"> (&ldquo;<U>Indemnitee</U>&rdquo;).</FONT></P>

<P STYLE="font: 11pt/12.1pt Times New Roman, Times, Serif; margin: 13.15pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.3pt">RECITALS</FONT></P>

<P STYLE="font: 11pt/12.85pt Times New Roman, Times, Serif; margin: 12.85pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
the Corporation, which is organized under the Nevada Revised Statutes (the &ldquo;<U>NRS</U>&rdquo;), wishes to enter into this
Agreement to set forth certain rights and obligations of the Indemnitee and the Corporation with respect to the Indemnitee&rsquo;s
service as a director of the Corporation;</FONT></P>

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 12.9pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
it is essential to the Corporation that it be able to retain and attract as directors and officers the most capable persons available;</FONT></P>

<P STYLE="font: 11pt/12.85pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
increased corporate litigation has subjected directors and officers to litigation risks and expenses, and the limitations on the
availability of directors and officers liability insurance have made it difficult for the Corporation to attract and retain such
persons;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
the Board of Directors of the Corporation (the &ldquo;<U>Board</U>&rdquo;) has determined that the difficulty in attracting and
retaining such persons is detrimental to the best interests of the Corporation&rsquo;s stockholders and that the Corporation should
contractually obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted
by applicable law so that they will serve the Corporation free from undue concern that they will not be so indemnified;</FONT></P>

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 12.9pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
Indemnitee performs a valuable service to the Corporation in Indemnitee&rsquo;s capacity as a director of the Corporation;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.85pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
the Corporation&rsquo;s Amended and Restated Bylaws (the &ldquo;<U>Bylaws</U>&rdquo;) include provisions providing for the indemnification
of the directors and officers of the Corporation, including persons serving at the request of the Corporation in such capacities
with other corporations or enterprises, as authorized by the NRS;</FONT></P>

<P STYLE="font: 11pt/12.7pt Times New Roman, Times, Serif; margin: 13pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
the Corporation&rsquo;s Certificate of Incorporation (the &ldquo;<U>Charter</U>&rdquo;), the Bylaws and the NRS, by their nonexclusive
nature, permit contracts between the Corporation and its directors and officers with respect to indemnification of such persons;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
in recognition of Indemnitee&rsquo;s need for (a) substantial protection against personal liability as a condition to Indemnitee&rsquo;s
service to the Corporation in Indemnitee&rsquo;s capacity as a director of the Corporation in addition to Indemnitee&rsquo;s reliance
on the Bylaws, which Indemnitee believes is inadequate in the present circumstances, and (b) specific contractual assurance of
Indemnitee&rsquo;s rights to full indemnification against risks and expenses (regardless of, among other things, any amendment
to or revocation of the Charter and/or the Bylaws, any change in the composition of the Corporation&rsquo;s Board, or a change
in control of the Corporation);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.85pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.85pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
the Corporation intends that this Agreement provide Indemnitee with greater protection than that which is provided by the Bylaws;
<FONT STYLE="letter-spacing: 0.1pt">and</FONT></FONT></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 12.45pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
in order to induce Indemnitee to serve as a director of the Corporation, the Corporation has determined and agreed to enter into
this Agreement with Indemnitee.</FONT></P>

<P STYLE="font: 11pt/12.7pt Times New Roman, Times, Serif; margin: 13pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOW,
THEREFORE, in consideration of Indemnitee&rsquo;s service as a director of the Corporation following the date hereof, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Corporation and Indemnitee
hereby agree as follows:</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnity of Indemnitee</U>. The Corporation agrees to hold harmless and indemnify Indemnitee to the fullest extent authorized
or permitted by law, the provisions of the Charter, and the Bylaws, as the same may be amended from time to time (but, only to
the extent that such amendment permits the Corporation to provide broader indemnification rights than such law, the Charter, or
the Bylaws permitted prior to adoption of such amendment). For purposes of this Agreement, the meaning of the phrase &ldquo;to
the fullest extent authorized or permitted by law&rdquo; shall include, but not be limited to: (i) to the fullest extent authorized
or permitted by the provision of the NRS that authorizes or contemplates additional indemnification by agreement, or the corresponding
provision of any amendment to or replacement of the NRS or such provision thereof; and (ii) to the fullest extent authorized or
permitted by any amendments to or replacements of the NRS adopted after the date of this Agreement that increase the extent to
which a corporation may indemnify its directors and officers.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 12.35pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Additional Indemnity</U>. In addition to and not in limitation of the indemnification otherwise provided for herein, and subject
only to the exclusions set forth in <U>Section 3</U> hereof, the Corporation further agrees to hold harmless and indemnify Indemnitee:</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
against any and all (i) expenses (including attorneys&rsquo; fees), retainers, court costs, transcript costs, fees of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees
and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing
to prosecute or defend, investigating, participating, or being or preparing to be a witness in any threatened, pending or completed
action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other
actual, threatened or completed proceeding, including any appeal thereof or related thereto (each, a &ldquo;<U>Proceeding</U>&rdquo;),
or responding to, or objecting to, a request to provide discovery in any Proceeding, (ii) damages, judgments, fines and amounts
paid in settlement and any other amounts that Indemnitee becomes legally obligated to pay (including any federal, state or local
taxes imposed on Indemnitee as a result of receipt of reimbursements or advances of expenses under this Agreement) and (iii) the
premium, security for, and other costs relating to any costs bond, supersedes bond, or other appeal bond or its equivalent, whether
civil, criminal, arbitrational, administrative or investigative with respect to any Proceeding (items under clauses, (i), (ii)
and (iii), collectively, the &ldquo;<U>Expenses</U>&rdquo;) actually and reasonably incurred by Indemnitee, or on Indemnitee&rsquo;s
behalf, because of any claim or claims made against or by him in connection with any Proceeding, whether formal or informal (including
an action by or in the right of the Corporation), to which Indemnitee is, was or at any time becomes a party or a witness, or
is threatened to be made a party to, a participant in or a witness with respect to, by reason of the fact that Indemnitee is,
was or at any time becomes a director or officer of the Corporation, or is or was serving or at any time serves at the request
of the Corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise (&ldquo;<U>Corporate
Status</U>&rdquo;)<B>;</B></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.5pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">against any and all Expenses actually and reasonably incurred by
Indemnitee, or on Indemnitee&rsquo;s behalf, if Indemnitee is, or is threatened to be made, a party to or a participant in any
Proceeding by or in the right of the Corporation to procure a judgment in its favor;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">against any and all Expenses actually and reasonably incurred by
Indemnitee, or on Indemnitee&rsquo;s behalf, if Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding
to which Indemnitee is not a party and is not threatened to be made a party; and</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">otherwise to the fullest extent as may be provided to Indemnitee
by the Corporation under the nonexclusivity provisions of the NRS, the Charter and the Bylaws.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.&#9;<U>Limitations
on Additional Indemnity</U>. No indemnity pursuant to <U>Section 2 </U>hereof shall be paid by the Corporation:</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.05pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
on account of any claim or Proceeding against Indemnitee for an accounting of profits made from the purchase or sale by Indemnitee
of securities of the Corporation pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as heretofore
or hereafter amended (the &ldquo;<U>Exchange Act</U>&rdquo;), or similar provisions of any federal, state or local law if the
final, nonappealable judgment of a court of competent jurisdiction finds Indemnitee to be liable for disgorgement under Section
16(b) of the Exchange Act;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.75pt 0 12pt 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.15pt">on account of Indemnitee&rsquo;s conduct that is established by a final, nonappealable judgment
of a court of competent jurisdiction as knowingly fraudulent or deliberately dishonest or that constituted willful misconduct;</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
for which payment is actually made to Indemnitee under (i) a valid and collectible insurance policy, including under any policy
of insurance purchased and maintained on Indemnitee&rsquo;s behalf by the Corporation or (ii) under a valid and enforceable indemnity
clause, bylaw, or agreement, including, but not limited to, an indemnity clause, bylaw, or agreement relating to another corporation,
partnership, joint venture, trust, or other enterprise for which Indemnitee is or was serving as a director or officer at the
request of the Corporation; <I>provided, that</I> indemnity pursuant to <U>Section 2</U> hereof shall be paid by the Corporation
in respect of any excess beyond payment actually received by Indemnitee under such insurance policy, clause, bylaw or agreement;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.15pt">if and to the extent indemnification is contrary to law, either as a matter of public policy,
or under the provisions of the Federal Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the
NRS, or any other applicable law; or</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.1pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in connection with any Proceeding (or part thereof) initiated by Indemnitee, against the Corporation or its directors, officers,
employees or other agents, unless (i) such indemnification is expressly required to be made by law, (ii) the Corporation has joined
in the Proceeding (or relevant part thereof), (iii) the Board has consented to the initiation of such Proceeding, (iv) such indemnification
is provided by the Corporation, in its sole discretion, pursuant to the powers vested in the Corporation under the NRS, or (v)
the Proceeding (or relevant part thereof) is initiated pursuant to <U>Section 12</U> hereof.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.1pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.1pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.75pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Continuation of Indemnity</U>. All agreements and obligations of the Corporation contained herein shall continue during the
period Indemnitee is a director or officer of the Corporation (or is or was serving at the request of the Corporation as a director
or officer of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long
as Indemnitee shall be subject to any possible claim or threatened, pending or completed Proceeding, whether civil, criminal,
arbitrational, administrative or investigative, including any appeal thereof or relating thereto, in respect of which Indemnitee
is granted rights of indemnification or advancement of Expenses hereunder, in each case, by reason of the fact of the Indemnitee&rsquo;s
Corporate Status.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Partial Indemnification</U>. Indemnitee shall be entitled under
this Agreement to indemnification by the Corporation for a portion of the Expenses, judgments, fines and amounts paid in settlement
and any other amounts that Indemnitee becomes legally obligated to pay in connection with any Proceeding referred to in <U>Section
2</U> hereof even if not entitled hereunder to indemnification for the total amount thereof, and the Corporation shall indemnify
Indemnitee for the portion thereof to which Indemnitee is entitled.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.05pt 0 12pt; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Notification and Defense of Claim</U>. To obtain indemnification
under this Agreement, Indemnitee shall submit to the Corporation a written request therefor. As soon as practicable, and in any
event, not later than thirty (30) days after Indemnitee becomes aware, by written or other overt communication, of any pending
or threatened litigation, claim or assessment, Indemnitee will, if a claim for indemnification in respect thereof is to be made
against the Corporation under this Agreement, notify the Corporation of such pending or threatened litigation, claim or assessment;
but the omission so to notify the Corporation will not relieve the Corporation from any liability which it may have to Indemnitee
otherwise under this Agreement, and any delay in so notifying the Corporation shall not constitute a waiver by Indemnitee of any
of Indemnitee&rsquo;s rights under this Agreement. With respect to any such pending or threatened litigation, claim or assessment
as to which Indemnitee notifies the Corporation of the commencement thereof:</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.25pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Corporation will be entitled to participate therein at its own expense;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt">except as otherwise provided below, the Corporation
may, at its option and jointly with any other indemnifying party similarly notified and electing to assume such defense, assume
the defense thereof, with counsel reasonably satisfactory to Indemnitee. After notice from the Corporation to Indemnitee of its
election to assume the defense thereof, the Corporation will not be liable to Indemnitee under this Agreement for any legal or
other expenses subsequently incurred by Indemnitee in connection with the defense thereof except for reasonable costs of investigation
or otherwise as provided below. Indemnitee shall have the right to employ separate counsel in such Proceeding but the fees and
expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense
of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Corporation, (ii) Indemnitee shall
have reasonably concluded, and so notified the Corporation, that there may be a conflict of interest between the Corporation and
Indemnitee in the conduct of the defense of such action, or (iii) the Corporation shall not in fact have employed counsel to assume
the defense of Indemnitee in connection with such action; in any of such cases the fees and expenses of Indemnitee&rsquo;s separate
counsel shall be at the expense of the Corporation. The Corporation shall not be entitled to assume the defense of any Proceeding
brought by or on behalf of the Corporation or as to which Indemnitee shall have made the conclusion provided for in clause (ii)
above; and</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the Corporation shall not be liable to indemnify Indemnitee under
this Agreement for any amounts paid in settlement of any action or claim effected without the Corporation&rsquo;s written consent,
which consent shall not be unreasonably withheld, conditioned or delayed. The Corporation shall not enter into any settlement
in connection with a Proceeding in any manner which would impose any Expenses, penalties (whether civil or criminal) or limitations
on Indemnitee without Indemnitee&rsquo;s written consent, which may be given or withheld in Indemnitee&rsquo;s sole and reasonable
discretion.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.05pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">7.&#9;<U>Expenses</U>.
The Corporation shall advance, to the extent not prohibited by law, all Expenses actually and reasonably incurred by Indemnitee
in connection with any Proceeding promptly following request therefor, but in any event no later than twenty (20) days after the
receipt by the Corporation of a written statement or statements requesting such advances (which shall include invoices received
by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references
to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall
not be included with the invoice) from time to time, whether prior to or after the final disposition of any Proceeding. The right
to advancement described in this <U>Section 7</U> is vested. Advances shall be unsecured and interest free. Advances shall be
made without regard to Indemnitee&rsquo;s ability to repay the expenses and without regard to Indemnitee&rsquo;s ultimate entitlement
to indemnification under the other provisions of this Agreement. The execution and delivery to the Corporation of this Agreement
shall constitute an undertaking by Indemnitee to the fullest extent required by law to repay all advances if and to the extent
that it is ultimately determined by a court of competent jurisdiction in a final, nonappealable judgment that Indemnitee is not
entitled to be indemnified by the Corporation, and Indemnitee shall qualify for advances immediately upon such execution and delivery.
The right to advances under this <U>Section 7</U> shall in all events continue until final disposition of any Proceeding, including
any appeal therein.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-indent: 40pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Red"><B></B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.25pt">8.&#9;<U>Contribution</U>.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.85pt 0 0; text-align: justify; text-indent: 1.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Whether or not the indemnification provided in <U>Section 2</U> is available, in respect of any Proceeding in which the Corporation
is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Corporation shall pay, in the first instance,
the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment
and the Corporation hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Corporation shall
not enter into any settlement of any Proceeding in which the Corporation is jointly liable with Indemnitee (or would be if joined
in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Without diminishing or impairing the obligations of the Corporation set forth in <U>Section 8(a)</U>, if, for any reason, Indemnitee
shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed Proceeding
in which the Corporation is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Corporation shall contribute
to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable
by Indemnitee in proportion to the relative benefits received by the Corporation and all officers, directors or employees of the
Corporation, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the
one hand, and Indemnitee, on the other hand, from the transaction from which such Proceeding arose&#894; <I>provided</I>, <I>however</I>,
that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted
by reference to the relative fault of the Corporation and all officers, directors or employees of the Corporation other than Indemnitee
who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other
hand, in connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other
equitable considerations which the law may require to be considered. The relative fault of the Corporation and all officers, directors
or employees of the Corporation, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such
Proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the
degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability
is primary or secondary and the degree to which their conduct is active or passive.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Corporation hereby agrees to fully indemnify and hold Indemnitee
harmless from any claims of contribution which may be brought by officers, directors or employees of the Corporation, other than
Indemnitee, who may be jointly liable with Indemnitee.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.25pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.25pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Red"><B></B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">(d)&#9;To the fullest extent
permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason
whatsoever, the Corporation, in lieu of indemnifying Indemnitee, shall contribute to the amount actually and reasonably incurred
by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses,
in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and
reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the
Corporation and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding&#894; and/or (ii)
the relative fault of the Corporation (and its directors, officers, employees and agents) and Indemnitee in connection with such
event(s) and/or transaction(s).</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0; text-indent: 40pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.25pt">9.&#9;<U>Presumptions
and Effect of Certain Proceedings</U>.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In making a determination with respect to Indemnitee&rsquo;s entitlement to indemnification hereunder, the person, persons or
entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification
under this Agreement if Indemnitee has submitted a request for indemnification in accordance with <U>Section 6</U> hereof. If
the Corporation contests any claim or assertion that Indemnitee is entitled to indemnification hereunder, the Corporation shall,
to the fullest extent not prohibited by law, have the burden of proof to overcome such presumption in connection with the making
by such person, persons, or entity of any determination with respect to Indemnitee&rsquo;s entitlement to indemnification.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.1pt">Without limiting the foregoing, if any Proceeding is disposed of on the merits or otherwise
(including a disposition without prejudice), without (i) the final disposition being adverse to Indemnitee, (ii) a final adjudication
by a court of competent jurisdiction that Indemnitee was liable to the Corporation, (iii) a plea of guilty (iv) a final adjudication
by a court of competent jurisdiction that Indemnitee did not act in good faith, and in a manner Indemnitee reasonably believed
to be in or not opposed to the best interests of the Corporation, or (v) with respect to any criminal proceeding, a final adjudication
by a court of competent jurisdiction that Indemnitee had reasonable cause to believe Indemnitee&rsquo;s conduct was unlawful,
Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect thereto.</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon
a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely
affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner
which he or she reasonably believed to be in or not opposed to the best interests of the Corporation or, with respect to any criminal
Proceeding, that Indemnitee had reasonable cause to believe that such Indemnitee&rsquo;s conduct was unlawful.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.1pt">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted
in good faith to the extent Indemnitee relied in good faith on (i) the records or books of account of the Corporation, including
financial statements , (ii) information supplied to Indemnitee by the officers of the Corporation in the course of their duties,
(iii) the advice of legal counsel for the Corporation or its Board or counsel selected by any committee of the Board or (iv )
information or records given or reports made to the Corporation by an independent certified public accountant, an appraiser, investment
banker or other expert selected with reasonable care by the Corporation or its Board or any committee of the Board.</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.25pt 0 0 0.55in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.25pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Information Sharing</U>. To the extent that the Corporation receives a request or requests from a governmental third party
or other licensing or regulating organization (the &ldquo;<U>Requesting Agency</U>&rdquo;), whether formal or informal, to produce
documentation or other information concerning an investigation, whether formal or informal, being conducted by the Requesting
Agency, and such investigation is reasonably likely to include review of any actions or failures to act by Indemnitee, the Corporation
shall promptly give notice to Indemnitee of said request or requests and any subsequent request. In addition, the Corporation
shall provide Indemnitee with a copy of any and all information or documentation that the Corporation shall provide to the Requesting
Agency.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.05pt"><U>No Imputation</U>. The knowledge and/or actions, or failure to act, of any director, officer,
agent or employee of the Corporation or the Corporation itself shall not be imputed to Indemnitee for purposes of determining
any rights under this Agreement.</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.85pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.25pt"><U>Enforcement</U>.</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt">(a)&#9;Any
right to indemnification or advances granted by this Agreement to Indemnitee shall be enforceable by or on behalf of Indemnitee
in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, (ii) no
disposition of such claim is made within ninety (90) days of request therefor&#894; (iii) advancement of Expenses is not timely
made pursuant to <U>Section 7,</U> (iv) payment of indemnification pursuant to this Agreement is not made within ten (10) days
after a determination has been made that Indemnitee is entitled to indemnification, or (v) the Corporation or any other person
or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation
or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be provided
to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by the Delaware Court of Chancery of Indemnitee&rsquo;s
entitlement to such indemnification or advancement of Expenses, and the Corporation shall not oppose Indemnitee&rsquo;s right
to seek any such adjudication in accordance with this Agreement. Indemnitee, in such enforcement action, if successful in whole
or in part, shall be entitled to be paid also the Expenses of prosecuting Indemnitee&rsquo;s claim. It shall be a defense to any
action for which a claim for indemnification is made under <U>Section 2</U> hereof (other than an action brought to enforce a
claim for advance or reimbursement of Expenses under this Agreement, <I>provided </I>that the required undertaking has been tendered
to the Corporation) that Indemnitee is not entitled to indemnification because of the limitations set forth in <U>Section 3</U>
hereof. Neither the failure of the Corporation (including the Board, any committee of the Board, or the Corporation&rsquo;s its
stockholders, or any subgroup of such directors or stockholders) to have made a determination prior to the commencement of such
enforcement action that indemnification of Indemnitee is proper in the circumstances, nor an actual determination by the Corporation
(including the Board, any committee of the Board, or the Corporation&rsquo;s stockholders, or any subgroup of such directors or
stockholders) that such indemnification is improper shall be a defense to the action or create a presumption that Indemnitee is
not entitled to indemnification under this Agreement or otherwise.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt">(b)
To the fullest extend not prohibited by law, the Corporation shall be precluded from </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">asserting
in any judicial proceeding commenced pursuant to this <U>Section 12</U> that the procedures and presumptions of this Agreement
are not valid, binding and enforceable and shall stipulate in any such court that the Corporation is bound by all the provisions
of this Agreement. If a determination shall have been made pursuant to this Agreement that Indemnitee is entitled to indemnification,
the Corporation shall be bound by such determination in any Proceeding commenced pursuant to this <U>Section 12,</U> absent (i)
a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statements
not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under
applicable law.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.85pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.25pt"><U>Subrogation</U>. In the event of </FONT>payment under this Agreement, the Corporation
shall be subrogated to the<FONT STYLE="letter-spacing: 0.25pt"> </FONT>extent of such payment to all of the rights of recovery
of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and
to enable the Corporation effectively to bring suit to enforce such rights.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>NonExclusivity of Rights</U>. The rights conferred on Indemnitee by this Agreement shall not be exclusive of any other right
which Indemnitee may have or hereafter acquire under any statute, provision of the Charter or Bylaws, agreement, vote of stockholders
or directors, or otherwise, both as to action in Indemnitee&rsquo;s official capacity and as to action in another capacity while
holding office. To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification
or advancement of Expenses than would be afforded currently under the Charter or Bylaws and this Agreement, it is the intent of
the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the
restrictions expressly set forth herein or therein. Except as expressly set forth herein, no right or remedy herein conferred
is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition
to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as expressly
set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent
assertion or employment of any other right or remedy.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.85pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Insurance</U>. To the extent that the Corporation maintains an
insurance policy or policies providing liability insurance for directors, trustees, general partners, managing members, officers,
employees, agents or fiduciaries of the Corporation, Indemnitee shall be covered by such policy or policies (including with respect
to prior service) to the same extent as the most favorablyinsured persons under such policy or policies in a comparable position.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.15pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt"><U>Enforcement;<B> </B>Survival of Rights</U>.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Corporation expressly confirms and agrees that the Corporation has entered into this Agreement and assumed the obligations
imposed on it hereby in order to induce Indemnitee to serve as a director of the Corporation, and the Corporation acknowledges
that Indemnitee is relying upon this Agreement in serving the Corporation in such capacity.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.85pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The rights conferred on Indemnitee by this Agreement shall continue after Indemnitee has ceased to be a director or officer of
the Corporation or to serve at the request of the Corporation as a director or officer agent of another corporation, partnership,
joint venture, trust or other enterprise, and shall inure to the benefit of Indemnitee&rsquo;s heirs, executors and administrators.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Corporation shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all
or substantially all of the business or assets of the Corporation, expressly to assume and agree to perform this Agreement in
the same manner and to the same extent that the Corporation would be required to perform if no such succession had taken place.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 13.05pt 0 0 0.55in; text-align: justify; text-indent: 1.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="letter-spacing: 0.15pt">The Corporation and Indemnitee agree herein that a monetary remedy for breach of this Agreement,
at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee
and the Corporation irreparable harm. Accordingly, the parties hereto agree that each of the Corporation and the Indemnitee may
enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual
damage or irreparable harm and that by seeking injunctive relief and/or specific performance, they shall not be precluded from
seeking or obtaining any other relief to which they may be entitled. The Corporation and Indemnitee further agree that they shall
be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions
and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Corporation
and Indemnitee acknowledge that in the absence of a waiver, a bond or undertaking may be required by the Delaware Court of Chancery,
and they hereby waive any such requirement of such a bond or undertaking.</FONT></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0 0.55in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Conflicts</U>.&#9;To the extent that any provision of this Agreement conflicts with the Charter, the Bylaws, or applicable
law, the Charter, the Bylaws, or such applicable law (as applicable) shall govern.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0 0.55in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 0.55pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Separability</U>. Each of the provisions of this Agreement is a separate and distinct agreement and independent of the others,
so that if any provision hereof shall be held to be invalid, illegal or unenforceable for any reason, (i) such invalidity, illegality
or unenforceability shall not affect the validity, legality or enforceability of the remaining provisions of this Agreement (including
without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that is not itself invalid, illegal or unenforceable) and such other provisions shall remain enforceable to the
fullest extent permitted by law; (ii) such provision or provisions shall be deemed reformed to the extent necessary to conform
to applicable law and to give the maximum effect to the intent of the parties hereto; and (iii) to the fullest extent possible,
the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any
such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed
so as to give effect to the intent manifested thereby. Furthermore, if this Agreement shall be invalidated in its entirety on
any ground, then the Corporation shall nevertheless indemnify Indemnitee to the fullest extent provided by the Charter (if applicable),
the Bylaws, the NRS or any other applicable law.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Governing Law</U>. This Agreement shall be governed by, and construed
and enforced in accordance with, the laws of the State of Delaware, without regard to its principles of conflicts of laws. The
Corporation and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in
connection with this Agreement may be brought in the Delaware Court of Chancery, (ii) consent to submit to the jurisdiction of
the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii)
waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (iv) waive,
and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has
been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.8pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Amendment and Termination</U>. No amendment, modification, termination
or cancellation of this Agreement shall be effective unless in writing signed by both parties hereto.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.95pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Identical Counterparts</U>. This Agreement may be executed in
one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute
but one and the same Agreement. Only one such counterpart need be produced to evidence the existence of this Agreement.</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Notices</U>. All notices, requests, demands and other communications
hereunder shall be in writing and shall be deemed to have been duly given (i) upon delivery if delivered by hand to the party
to whom such communication was directed or (ii) upon the third business day after the date on which such communication was mailed
if mailed by certified or registered mail with postage prepaid:</FONT></P>

<P STYLE="font: 11pt/12.8pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 0.55in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/11.95pt Times New Roman, Times, Serif; margin: 1pt 0 0 1.6in; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If to Indemnitee, at the address indicated on the signature page hereof.</FONT></P>

<P STYLE="font: 11pt/11.95pt Times New Roman, Times, Serif; margin: 13.7pt 0 0 1.6in; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If to the Corporation, to:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">Relmada
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">757
Third Avenue, 21<SUP>st</SUP> Floor</FONT></P>

<P STYLE="font: 11pt/11.95pt Times New Roman, Times, Serif; margin: 1pt 0 0 1.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.1pt">New
York, NY 10017</FONT></P>

<P STYLE="font: 11pt/11.95pt Times New Roman, Times, Serif; margin: 0.8pt 0 0 1.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">Attention:&#9;Chief
Executive Officer</FONT></P>

<P STYLE="font: 11pt/11.95pt Times New Roman, Times, Serif; margin: 13.7pt 0 0 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0.05pt">or
to such other address as may have been furnished to Indemnitee by the Corporation.</FONT></P>

<P STYLE="font: 11pt/12.7pt Times New Roman, Times, Serif; margin: 13pt 0 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22.&#9;<U>Headings</U>.
The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute part of
this Agreement or to affect the construction hereof.</FONT></P>

<P STYLE="font: 11pt/12.25pt Times New Roman, Times, Serif; margin: 13.65pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[<I>Remainder
of Page Intentionally Left Blank</I>]</FONT></P>

<P STYLE="font: 11pt/12.25pt Times New Roman, Times, Serif; margin: 13.65pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.</FONT></P>

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPANY:</B></FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RELMADA THERAPEUTICS, INC.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">By: /s/ Sergio Traversa</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Sergio Traversa</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>INDEMNITEE:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Charles J. Casamento&#9;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Charles J. Casamento</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;11</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 12pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0 3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 12pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<P STYLE="font: 12pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0 3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 12pt/12.75pt Times New Roman, Times, Serif; margin: 0.45pt 0 0 3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>f8k071415ex99i_relmadather.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Relmada
Therapeutics Appoints Charles J. Casamento to Its Board of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Seasoned executive has more than four
decades of industry experience</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NEW YORK, July 16, 2015</B> - Relmada
Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced
today Charles J. Casamento has joined the company&rsquo;s board of directors, completing the slate of three independent directors.
Mr. Casamento will also serve as chairman of the audit committee for Relmada Therapeutics.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since 2007 Mr. Casamento has been
executive director and principal of The Sage Group, a health care advisory group. He was president and CEO of Osteologix from
October 2004 until April 2007. Mr. Casamento was the founder of Questcor Pharmaceuticals where he was president, CEO and
chairman. At RiboGene Inc. he was president, CEO and chairman and he was also co-founder, president and CEO of Indevus
(formerly Interneuron Pharmaceuticals). He has held senior management positions at Genzyme Corporation, American Hospital
Supply, Johnson &amp; Johnson, Hoffmann-LaRoche and Sandoz. He holds a bachelor&rsquo;s degree in Pharmacy from Fordham
University and an M.B.A. from Iona College.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Charles Casamento has a broad
and deep business background, and brings a wealth of experience in the healthcare sector at a time when it will be most valuable
to our company,&rdquo; said Sandesh Seth, Chairman at Relmada Therapeutics. &ldquo;My goal since the company&rsquo;s inception
was to surround our management team with a world class board of directors comprised of accomplished medical, healthcare and business
professionals whose skill sets, relationships and knowledge could be leveraged to create shareholder value. The addition of Mr.
Casamento represents another solid step in that direction.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Given his extensive senior-level
experience at several established pharmaceutical and biotechnology companies, I believe that Charles Casamento will add to the
level of talent that currently exists on our Board,&rdquo; stated Sergio Traversa, CEO of Relmada Therapeutics. &ldquo;Importantly,
the appointment of a financial expert and third independent board member addresses one of the requirements for our planned uplisting
to NASDAQ.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;With a diversified portfolio
of unique product candidates at various stages of clinical development, I believe Relmada is poised to become a leading pain management
company and I am therefore very pleased to be joining the board of directors at this exciting time for the company,&rdquo; said
Mr. Casamento.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">Relmada
Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">546
Fifth Avenue 14th Fl. | New York, NY 10036</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">Phone:
(212) 702-7163</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">W:
www.relmada.com | E: info@relmada.com</FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Relmada Therapeutics, Inc.
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Relmada Therapeutics is a clinical-stage,
publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical
entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio
of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor
antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic
mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015),
its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company&rsquo;s product development
efforts are guided by the internationally recognized scientific expertise of its research team. The Company&rsquo;s approach is
expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet
medical needs. For more information, please visit Relmada&rsquo;s website at: <U>www.relmada.com</U>.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This news release contains &ldquo;forward-looking
statements.&rdquo; These statements are based on management&rsquo;s current expectations and involve risks and uncertainties, which
may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include
statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Contact</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Investor Contact:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Michael Becker, SVP of Finance and Corporate Development</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Relmada Therapeutics Inc.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Tel: 212-376-5776</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">mbecker@relmada.com</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Media Contact:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Salisbury</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Berry &amp; Company Public Relations</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Tel: 212-253-8881</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">dsalisbury@berrypr.com</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">Relmada
Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">546
Fifth Avenue 14th Fl. | New York, NY 10036</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">Phone:
(212) 702-7163</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">W:
www.relmada.com | E: info@relmada.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #7F7F7F"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!^`+0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HJ*XN(;2VDN;B5(H8E+O(YP%`ZDFN6MOB/H=TY,:7@
MM0V#=F#]W]>N0/<BKA3G/X5<SJ5J=.W/)*YUU%(CK(BNC!D895E.01ZTM0:!
M116!XPUG^P_#\UT"020@([9JZ<'.2BNIG5JJE!SELBUJ/B'3=+'^DS'Z(I-+
MI/B+2M;W"PO$E=/O1]&'X&OGSQ1J&I7EHMQ)),D3K\G/4"N2\):KJ%CXECEL
MI&2=6!4Y)).>GX]*]"K@X0M"[YGUZ'DT,QJU$ZC2Y5TZ_?\`\`^Q**ALY_M5
ME!<;=OFQJ^/3(S4U>8U;0]E.ZN@HHHH&%%%%`!1110`4444`%%%%`!1110`4
M444`<E\2].O-5\!:A:V.XR'8[(O5T5P6'Y"O-[V)O"T.GV5Q<!Y+F#=+;IU4
M^A]>M>O:Q>(BM&>8X@'E`_B/\*?B?Z>M-LM"LD,=]>VEO)J&-S3.@)4]<`GH
M!TKKPV*=!^1P8W`QQ*UWZ>11\$S);^&+*PDN!+/;IM;U49)`(/(P"!^%=-N&
MW=D8]:P-;;2`GVBX989%^[<*VQ@?8CEJP&UO4KV(P:5!/*J#YKB=,D^X0?UK
MED[ML[8QY8J*Z'77^M6>GPF6:5%4?Q,V!_\`7_"N"UW5;SQ=$^G6-E+-`_5V
M7`'H0/ZFM#1]"L=1N/M&IWSW5R.3&Y^9?P[?@/QKM46RTZURGDV\"]6R%7\3
M3A)QDI+="J0C.#C+9GR_K5W?6Z-874#K)$2A!'2M'X:>$[S5]8-R(F5%/^LQ
MP@]<_P`J]*TVQM?%/CFXFNK:*XMH2\K!UR"/NH/YG\*])M[:WM(5AMH(X8EZ
M)&H4#\!7?/'<SYK:GET\KY5R-^Z]^['0Q)!#'%&,(BA5'L.*?117G'KA1110
M`4444`%%%%`!1110`4444`%%%%`%#6M7M-!T>ZU2^<K;VZ;VP,D]@![DX`^M
M>3Q?$O6-4G\_S5L;=C\D,:J2H[;F(.3],"NP^*]B]]X%G5-VV*:.5]O]T'_'
M%>$WVJP?V='`K*C)GD+@GZUZ>!I4^5U)JYXN9UZO,J5)M>A[-:^(HGN(I;F=
M9;>-C-O8;6>3MN`ZX[8]!5XZWJNN2F/3+9MO>61>%^@Z#\:\B\(W4NHW=KIL
M3-))-,@'J.>?PQG-?2<44<$:QQ1K&B]%48`K'&TH0DI0V9T996J3@X5-7%[G
M,V/@]/.%UJD[W5QUY;@?C_ABNEA@BMXQ'#&L:#HJC%245Q'I%#4-&LM2&9HM
MLH^[+&=KC\:\O\97LNDZO#IE[<_:(U4RQ23>X[CN>.M>OUP'Q(\''Q9!;I$Z
M1W46=DN#D`]CZBNC"U(TZG,U<Y,;1E6I<D78X/P1K%U_PEMD]M*P:6=8)8]W
MRR1MUR/4=17O=>6?#KX>/X7U)KN[E2XN2"L;X.$SUP/4^M>ITJ\H-I05K(>&
MA4BI.H[W84445@=04444`%%%%`!1110`4444`%%5;W4K'351KZ[@ME<X4RN%
MS],U3_X2C0/^@S8?^!"_XU2A)JZ1$JL(NS:-:BF131SQ++#(DD;#*NAR"/8U
MGR^(]$@E>*75K))$8JRM.H((Z@C-"C)Z)#E.,5=L=JL<\EE*B!&1D(97&00>
MH-?/.N?#;5)M0D>R@5(6;(4GI]*^A(]7TS5"UO9:A:W$N-Q2*4,<#O@?A4<D
M5N+A;4RQBX=2ZQ%OF*CJ0/2M(.4-#&:A4L]SSOX9^$I/#TS2R0I]L=<>:_)`
M[A?2O64W;?FZU2BL]A#`8(-3WE_::?$LMY<Q6\;-M#2N%!/IS4R;FRX)0CV1
M8HI`01D'(-0W=[:V$'G7ES%;Q9V[Y7"C/IDU"3;LC1M)79/3#&K')'-.5E=0
MRD%6&01W%075]:6(C-W<PP"1MB>8X7<?09H2=[(&TE=DHC53D"GT53O-6T[3
MG5+V^MK9F&5$LH4D?C0DV[(&U%7>A<HK*'B?02<#6;#_`,"%_P`:TT=)$5XV
M5T895E.013<91W0HSC+X7<=14<\\-K`\]Q*D42#+.[8"CW-$$\5S`D\$J2Q.
M,JZ'(8>QI6=KCNKV)****0PHHHH`****`..\:ND6K>'7DLWO$%Q)F!$#L_R=
M`#P::VI6.T_\4-?GCI]@C_QKH=1TA=0U+3+PS%#8R-(%"YWY7&/:M*NGVT5"
M*M>WKW9QO#R=24KVOY)]$<QX`CV>$H&#+LDDD=44Y\L%S\OU%8&CW=M!<ZRL
MWARZU)CJ<Y\Z*U20#D?+DGK_`(UVFA:0NAZ6MDLQF`D=]Y7'WF)_K63%X7U*
MTGNWL/$4MM%<W#W#1BU1@&8\\G\*T56#G-M[^OZ&4J-10II+9:[=O/0NZ%):
MW+S21:#+ICH`NZ:W6,N#Z8Z]/Y53N_\`DI.G?]@Z7_T(5H:;IFJVEWYMYKLE
M[%M(\IK=$&?7*\U!J_A^XO\`5[?4[/5'L9X86A!6%7R"<G[U9J45-ZZ-/O\`
M\.:N,W27NZIKMW];&]7)^.[:*\AT6UG7=#-J<4;C/4$,#5^UTC6H;N*6?Q)+
M<1*V7B-I&H<>F1R*M:OI"ZLU@6F,7V2Z2Y&%SN*YX]NM33<:=1._YE55*M2<
M>6WK;_-F1X9O9M-NIO#6I2$SVB[[69S_`*Z#L?JO0_\`UJYSQ*[^*--U;5R3
M_96GQM'9#.!-+D!I/H.@_P#UUV/B/PU;^(H(0\TEM/"QV3Q?>"D89?H14U]H
M%O=>&I-#@/V:W:(1*57.T#'Y]*UA6A&2J=7OY=W\_P#,QJ8>K*#I/X4G;S[)
M^GXZ%ZQ_Y!UM_P!<E_D*X61M+\7ZMJ%QJ-];QZ?;HUI9*\RJ2Y^]*`3ZXQ79
M7VG2W6AOIT-VUNSQ"+SE7)`Q@X'J152V\):#;VT4/]DV<GEH%WR0JS-CN3CD
MU%*I"%Y7U-*U*I4Y8V5EO?J5O!VLMJ.FR6=S,DE]8-Y$SHP82`?=<'N"/U!J
MOJ5O!=?$73H[B&.9/[/E.V10PSN'8UH1>&+2SUR#4M-V66R,Q3011@),IY&0
M.A![TW5_#]Q?ZO;ZG9ZH]C/#"T(*PJ^03D_>IJ=/VCE%V33^3$X5?9*,E=IK
MYI>I?;0])92K:99$$8(\A?\`"L;P#E?#/E<[(KF9(P>RAS@5(V@Z^RE3XLN,
M'@[;.('\ZU]+TR'1]+BL+4MLB!PS\EB3DD^Y)S4RDE3<>:]VN_GW+A%NJI\G
M+9/MUMV;.9\27UKJWB&UT":ZABLH"+F_,D@4/CE(^?4\GVH\-7UMI6OW7AZ*
MZAFLY2;FP:.0,%!Y:/CT.2/:M+3_``?IEO%*;^"'4;J:5I9;BXA4LQ/IUP/:
MB_\`!^F7$<36$$.G74,JRQ7%O"H*D=B.,@^E:>TI<OL[NWZ]_P"NAA[*OS>U
MLKW^=NW;_@G0T4@S@9Z]Z6N,]$****`"BBB@`HHHH`#TX&:SK/4+FYNYH)+$
MPB$A7?S0W)`(X'L:T:C2"..661%P\I#.<]2``/T`IIJSN3)-M69F1>(K&9+;
M9(IEGE$7DAQO4Y(Y'X4X:T&U62Q2*/='((R6G56/R@Y"]3P?TJXMA:K##"(@
M(X7#QC)^5@<Y_6F?V9;?:FN5\Y9'<.VV9PK$`#)4''0#M6EZ>NAE:K9:E"_\
M1QV-U<PM$A^SJ&8M.J%LC/R@]:MZAJ\6GPPR-%)(9/FV*!N"`99B#V`_H.]6
M&LK=_M&Z,'[2-LO)^88Q_*F2:78S2K)-:Q2LJ"-3(N[:OH`>E*]/30;C5UL_
M^`0:CK$=A]EP$D%QG8S2JBX`SU-0OK\:Z7%>^3CS)O)`:50N<D9W=-O'6K\6
MGVL`MQ'$%%N"L0R?D!Z@>U.NK.&\C5)@Q",'4JY4@CN""#0G#30'&KJ[E=-3
M!L8KEXQB258P(Y`X^9@H.1QWJ5KL_:I[:.(O+%$L@&0`VXL`/_'?UH;3K=[0
MVK^8\98-\TK%@0<@ALY&"/6EM;""T>1XA(7D`#/)(SD@9P,L3QR?SI>Y8I*I
M=%2#5I9+2ZN9;)HH[</G]X&+%,Y''TI\VI2BXCM[:T:>5XO.(,@0*N<#D]ZM
M?8X/L\L'E_NYBQ=<GG=G=^>34<^FVT[I(PD5T78K1RLAV^F5(R*=X7V%RU+;
M_P!?<5[S5S96=M++;%))VV;)9%4(<$_,W3MQZ\58TZ]&H6@G"!?F*X60..#V
M(X(I#I=H;:&W".B0G,921E93SGY@<\Y-2VMG!91&.!2`S%V)8L68]22>2:3<
M.73<(JIS7;T)Z***@U"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
;`****`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
